Paroxysmal Nocturnal Hemoglobinuria
New Developments
December 2010
Two recent discoveries have changed PNH practice. First, a therapeutic antibody Eculizumab, which is directed against complement has been developed for clinical use, resulting in less requirements for transfusion and improved life quality. Importantly, for the clinical practice, the use of antibody is associated with less complications, but the percentage of PNH cells often increases due to inhibition of lysis.
New Developments |
Jump to section:
- Introduction
- Paroxysmal Nocturnal Hemoglobinuria
- Prevalence
- Pathogenesis
- Paroxysmal Nocturnal Hemoglobinuria
- Progression
- New Developments
- New Developments, cont.
- Role of Laboratory Testing
- International PNH Group Recommendations: Who to Test?
- Diagnosis
- International PNH Group Recommendation: How to Test?
- Normal
- New WBC PNH
- Sensitivity and Reference Interval
- Interpretation and Reporting
- PNH—Summary
- Questions?
External
link
PDF
document
Excel
document
Word
document